Prognostic value of the combination of serum levels of vascular endothelial growth factor, C-reactive protein and contrast-enhanced ultrasound in patients with primary liver cancer who underwent transcatheter arterial chemoembolization

References

• Chong RJ, Abdullah MS, Hossain MM, et al. Rising incidence of primary liver cancer in Brunei Darussalam. Asian Pac J Cancer Prev. 2013;14(6):3473–3477. [PubMed: 23886131].
   PubMedGoogle Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538. [PubMed: 16879891].
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Tsao L, Hsing AW, et al. International trends and patterns of primary liver cancer. Int J Cancer. 2001;94(2):290–296. [PubMed: 11668511].
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822): 1245–1255. [PubMed: 22353262].
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu Q, Wu M, et al. GAB2 promotes cell proliferation by activating the ERK signaling pathway in hepatocellular carcinoma. Tumour Biol. 2016;37(9):11763–11773. [PubMed: 27026230].
   PubMedGoogle Scholar
• European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. [PubMed: 22424438].
   PubMed Web of Science ®Google Scholar
• Park Y, Kim SU, Kim BK, et al. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int. 2016;36(1):100–107. [PubMed: 26013186].
   PubMed Web of Science ®Google Scholar
• Xu L, Peng ZW, Chen MS, et al. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. J Hepatol. 2015;63(1):122–130. [PubMed: 25725438].
   PubMed Web of Science ®Google Scholar
• Kadalayil L, Benini R, Pallan L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013;24(10):2565–2570. [PubMed: 23857958].
   PubMed Web of Science ®Google Scholar
• Hucke F, Pinter M, Graziadei I, et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol. 2014;61(6):1287–1296. [PubMed: 25016222].
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Arizumi T, Allara E, et al. Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification. Clin Gastroenterol Hepatol. 2015;13(6):1204–1208 e1202. [PubMed: 25528009].
   PubMed Web of Science ®Google Scholar
• Kim BK, Shim JH, Kim SU, et al. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. Liver Int. 2016;36(1):92–99. [PubMed: 25950442].
   PubMed Web of Science ®Google Scholar
• Jun CH, Ki HS, Lee KH, et al. Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE. Clin Mol Hepatol. 2013;19(1):70–77. [PubMed: 23593612].
   PubMedGoogle Scholar
• Allin KH, Nordestgaard BG, Flyger H, et al. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 2011;13(3):R55. [PubMed: 21639875].
   PubMed Web of Science ®Google Scholar
• Kong F, Gao F, Chen J, et al. Elevated serum C-reactive protein level predicts a poor prognosis for recurrent gastric cancer. Oncotarget. 2016;7(34):55765–55770. [PubMed: 27303917].
   Web of Science ®Google Scholar
• Tian R, Yan H, Zhang F, et al. Cumulative score based on preoperative plasma fibrinogen and serum C-reactive protein could predict long-term survival for esophageal squamous cell carcinoma. Oncotarget. 2016;7(38):61533–61543. [PubMed: 27517497].
   Web of Science ®Google Scholar
• Bodner-Adler B, Kimberger O, Schneidinger C, et al. Prognostic significance of pre-treatment serum C-reactive protein level in patients with adenocarcinoma of the uterine cervix. Anticancer Res. 2016;36(9):4691–4696. [PubMed: 27630314].
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Onoda H, Takano K, et al. Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Med Oncol. 2012;29(4):2800–2808. [PubMed: 22460836].
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Onoda H, Imai N, et al. C-reactive protein as a prognostic marker in patients with hepatocellular carcinoma. Hepatogastroenterology. 2015;62(140):966–970. [PubMed: 26902038].
   PubMedGoogle Scholar
• Shim JH, Park JW, Kim JH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 2008;99(10):2037–2044. [PubMed: 19016764].
   PubMed Web of Science ®Google Scholar
• Wang B, Xu H, Gao ZQ, et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008;49(5):523–529. [PubMed: 18568538].
   PubMed Web of Science ®Google Scholar
• Jia WR, Tang L, Wang DB, et al. Three-dimensional contrast-enhanced ultrasound in response assessment for breast cancer: a comparison with dynamic contrast-enhanced magnetic resonance imaging and pathology. Sci Rep. 2016;6:33832. [PubMed: 27652518].
   PubMed Web of Science ®Google Scholar
• Shiozawa K, Watanabe M, Ikehara T, et al. Therapeutic evaluation of sorafenib for hepatocellular carcinoma using contrast-enhanced ultrasonography: preliminary result. Oncol Lett. 2016;12(1):579–584. [PubMed: 27347183].
   PubMed Web of Science ®Google Scholar
• Fan X, Guo Y, Wang L, et al. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles. Int J Nanomedicine. 2016;11:3939–3950. [PubMed: 27574424].
   PubMed Web of Science ®Google Scholar
• Xu HX, Lu MD. The current status of contrast-enhanced ultrasound in China. J Med Ultrason (2001). 2010;37(3): 97–106. [PubMed: 27278008].
   PubMed Web of Science ®Google Scholar
• Schutte K, Schulz C, Malfertheiner P. Nutrition and hepatocellular cancer. Gastrointest Tumors. 2016;2(4): 188–194. [PubMed: 27403413].
   PubMed Web of Science ®Google Scholar
• Glassner K, Schneider W. [Disseminated intravascular coagulation as a hemorrhagic complication in surgery]. Med Monatsschr. 1972;26(5): 233–235. [PubMed: 5084175].
   PubMedGoogle Scholar
• Ng CS, Wang X, Faria SC, et al. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. AJR Am J Roentgenol. 2010;194(1):166–171. [PubMed: 20028919].
   PubMed Web of Science ®Google Scholar
• Quaia E, Calliada F, Bertolotto M, et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology. 2004;232(2):420–430. [PubMed: 15286314].
   PubMed Web of Science ®Google Scholar
• Albrecht T, Blomley M, Bolondi L, et al. Guidelines for the use of contrast agents in ultrasound. January 2004. Ultraschall Med. 2004;25(4):249–256. [PubMed: 15300497].
   PubMed Web of Science ®Google Scholar
• Shao Q, Ren P, Li Y, et al. Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma. Int J Oncol. 2012;41(3):1061–1067. [PubMed: 22692946].
   PubMed Web of Science ®Google Scholar
• Macias Rodriguez MA, Rendon Unceta P, Navas Relinque C, et al. Ultrasonography in patients with chronic liver disease: its usefulness in the diagnosis of cirrhosis. Rev Esp Enferm Dig. 2003;95(4):258–264. [PubMed: 12826003].
   PubMed Web of Science ®Google Scholar
• Nakao N, Uchida H, Kamino K, et al. Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis. Cardiovasc Intervent Radiol. 1994;17(2):76–80. [PubMed: 8013027].
   PubMed Web of Science ®Google Scholar
• Matsuo N, Uchida H, Sakaguchi H, et al. Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma: study based on lipiodol accumulation patterns and histopathologic findings. Semin Oncol. 1997;24(2 Suppl 6):S6-61–S66-70. [PubMed: 9151919].
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1): 52–60. [PubMed: 20175033].
   PubMed Web of Science ®Google Scholar
• Sieghart W, Hucke F, Pinter M, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology. 2013;57(6):2261–2273. [PubMed: 23316013].
   PubMed Web of Science ®Google Scholar
• Park W, Chung YH, Kim JA, et al. Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: focused on the recurrence patterns. Hepatol Res. 2013;43(12):1304–1312. [PubMed: 23442052].
   PubMed Web of Science ®Google Scholar
• Peveling-Oberhag J, Seiz A, Doring C, et al. MicroRNA profiling of laser-microdissected hepatocellular carcinoma reveals an oncogenic phenotype of the tumor capsule. Transl Oncol. 2014;7(6):672–680. [PubMed: 25500075].
   PubMed Web of Science ®Google Scholar
• Yang T, Zhang H, Cai SY, et al. Elevated SHOX2 expression is associated with tumor recurrence of hepatocellular carcinoma. Ann Surg Oncol. 2013;20 Suppl 3:S644–649. [PubMed: 23851611].
   PubMed Web of Science ®Google Scholar
• Guerrini GP, Pinelli D, Di Benedetto F, et al. Predictive value of nodule size and differentiation in HCC recurrence after liver transplantation. Surg Oncol. 2015;25(4):419–428. [PubMed: 26403621].
   PubMed Web of Science ®Google Scholar
• Rennert J, Georgieva M, Schreyer AG, et al. Image fusion of contrast enhanced ultrasound (CEUS) with computed tomography (CT) or magnetic resonance imaging (MRI) using volume navigation for detection, characterization and planning of therapeutic interventions of liver tumors. Clin Hemorheol Microcirc. 2011;49(1–4):67–81. [PubMed: 22214679].
   PubMed Web of Science ®Google Scholar
• Strobel D, Bernatik T, Blank W, et al. Diagnostic accuracy of CEUS in the differential diagnosis of small (</= 20 mm) and subcentimetric (</= 10 mm) focal liver lesions in comparison with histology. Results of the DEGUM multicenter trial. Ultraschall Med. 2011;32(6):593–597. [PubMed: 22161556].
   PubMed Web of Science ®Google Scholar
• Sparchez Z, Mocan T, Radu P, et al. Contrast enhanced ultrasonography in assessing the treatment response to transarterial chemoembolization in patients with hepatocellular carcinoma. Med Ultrason. 2016;18(1):96–102. [PubMed: 26962561].
   PubMed Web of Science ®Google Scholar
• Yang YL, Yang RJ, Liu X, et al. Correlations between the time-intensity parameters of contrast-enhanced ultrasound and clinical prognosis of hepatocellular carcinoma. Clin Imaging. 2013;37(2):308–312. [PubMed: 23465984].
   PubMed Web of Science ®Google Scholar
• Peng C, Liu LZ, Zheng W, et al. Can quantitative contrast-enhanced ultrasonography predict cervical tumor response to neoadjuvant chemotherapy? Eur J Radiol. 2016;85(11):2111–2118. [PubMed: 27776666].
   PubMed Web of Science ®Google Scholar
• Gao Y, Zheng DY, Cui Z, et al. Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation. World J Gastroenterol. 2015;21(36):10418–10426. [PubMed: 26420968].
   PubMed Web of Science ®Google Scholar
• Zheng W, Xiong YH, Han J, et al. Contrast-enhanced ultrasonography of cervical carcinoma: perfusion pattern and relationship with tumour angiogenesis. Br J Radiol. 2016;89(4):20150887. [PubMed: 27340932].
   PubMedGoogle Scholar
• Song J, Wang LZ, Li X, et al. Polymorphisms of vascular endothelial growth factor on prognosis in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization treatment. Genet Mol Res. 2014;13(4):8946–8953. [PubMed: 25366785].
   PubMed Web of Science ®Google Scholar
• Zheng Z, Zhou L, Gao S, et al. Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis. Int J Med Sci. 2013;10(6):653–664. [PubMed: 23569429].
   PubMed Web of Science ®Google Scholar
• Li Z, Xue TQ, Chen XY. Predictive values of serum VEGF and CRP levels combined with contrast enhanced MRI in hepatocellular carcinoma patients after TACE. Am J Cancer Res. 2016;6(10): 2375–2385. [PubMed: 27822426].
   PubMed Web of Science ®Google Scholar